Targeted Disease(s):
COPD

Purpose of Study:

Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPD

Study Dates:
February 12, 2021 - October 17, 2025

Type of Study:
Pre-Market

Study Design:
Controlled Design

Study Location:
Nationwide

Contact:

800-633-1610, option 6
[email protected]

ClinicalTrails.gov Identifier:
NCT04751487

Register for Trial
Asthma Basics Workshop - National
, | Feb 21, 2024
Asthma Basics Workshop - National
, | Mar 20, 2024